"Take is Elestrin for instance. It's a treatment for menopause symptoms - a market estimated to be worth anywhere from $2 billion to $8 billion per year. The wide variances in its size underscore the idea that many women don't treat it, but would if the right product was available. Elestrin is already FDA-approved.
BioSante is also developing Bio T-Gel for male hypogonadism, and The Pill-Plus contraceptive. The latter will be a $17 billion market within three years."
Link is there for a read, but the momo hasn't even started. For instance, the pill somx was doing was only estimated at $3 billion
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.